L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia

Cerebral Cortex

Volumn 26, Issue 11, 2016, Pages 4253-4264

  Suarez, Luz M ^a,b   Solis, Oscar ^a,b   Aguado, Carolina ^c   Lujan, Rafael ^c   Moratalla, Rosario ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Universidad Castilla La Mancha   (Spain)

Author keywords

L DOPA induced dyskinesia; medium spiny neurons; neuronal excitability; Parkinson's disease; striatum

Indexed keywords

LEVODOPA; ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; OXIDOPAMINE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; CELL DENSITY; CONTROLLED STUDY; DENDRITIC SPINE; DYSKINESIA; ELECTRON MICROSCOPY; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MEDIUM SPINY NEURON; MEMBRANE STEADY POTENTIAL; MOUSE; MUSHROOM; NONHUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; SYNAPSE; SYNAPTIC TRANSMISSION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; EXCITATORY POSTSYNAPTIC POTENTIAL; GENETICS; METABOLISM; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; SPINE; TRANSGENIC MOUSE; ULTRASTRUCTURE;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SPINE; SYMPATHOLYTICS;

EID: 84994560528     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhw263     Document Type: Article

References (51)

1. Albin RL, Young AB, Penney JB. 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:366-375.
2. Andre VM, Cepeda C, Cummings DM, Jocoy EL, Fisher YE, William Yang X, Levine MS. 2010. Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. Eur J Neurosci. 31:14-28.
3. Azdad K, Chavez M, Don Bischop P, Wetzelaer P, Marescau B, De Deyn PP, Gall D, Schiffmann SN. 2009. Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion. PloS One. 4:e6908.
4. Bolam JP, Hanley JJ, Booth PA, Bevan MD. 2000. Synaptic organisation of the basal ganglia. J Anat. 196 (Pt 4):527-542.
5. Bourne JN, Harris KM. 2008. Balancing structure and function at hippocampal dendritic spines. Ann Rev Neurosci. 31:47-67.
6. Calabresi P, Centonze D, Bernardi G. 2000. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 23 (Suppl 10):S57-S63.
7. Calabresi P, Centonze D, Gubellini P, Marfia GA, Bernardi G. 1999. Glutamate-triggered events inducing corticostriatal long-term depression. J Neurosci. 19:6102-6110.
8. Calabresi P, Pisani A, Mercuri NB, Bernardi G. 1993. Heterogeneity of metabotropic glutamate receptors in the striatum: electrophysiological evidence. Eur J Neurosci. 5:1370-1377.
9. Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R. 2009. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry. 66:603-613.
10. DayM, Wang Z, Ding J, An X, InghamCA, Shering AF, Wokosin D, Ilijic E, Sun Z, Sampson AR, Mugnaini E, Deutch AY, Sesack SR, Arbuthnott GW, Surmeier DJ. 2006. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci. 9:251-259.
11. Deutch AY, Colbran RJ, Winder DJ. 2007. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord. 13 (Suppl 3):S251-S258.
12. Dumitriu D, Laplant Q, Grossman YS, Dias C, Janssen WG, Russo SJ, Morrison JH, Nestler EJ. 2012. Subregional, dendritic compartment, and spine subtype specificity in cocaine regulation of dendritic spines in the nucleus accumbens. J Neurosci. 32:6957-6966.
13. Feyder M, Bonito-Oliva A, Fisone G. 2011. L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci. 5:71.
14. Fieblinger T, Graves SM, Sebel LE, Alcacer C, Plotkin JL, Gertler TS, Chan CS, Heiman M, Greengard P, Cenci MA, Surmeier DJ. 2014. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Comm. 5:5316.
15. Galarraga E, Hernandez-Lopez S, Reyes A, Barral J, Bargas J. 1997. Dopamine facilitates striatal EPSPs through an L-type Ca2+ conductance. Neuroreport. 8:2183-2186.
16. Gardoni F, Picconi B, Ghiglieri V, Polli F, Bagetta V, Bernardi G, Cattabeni F, Di Luca M, Calabresi P. 2006. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J Neurosci. 26:2914-2922.
17. Gerfen CR, Surmeier DJ. 2011. Modulation of striatal projection systems by dopamine. Ann Rev Neurosci. 34:441-466.
18. Grueter BA, Robison AJ, Neve RL, Nestler EJ, Malenka RC. 2013. FosB differentially modulates nucleus accumbens direct and indirect pathway function. Proc Natl Acad Sci USA. 110 (5):1923-1928.
19. Harris KM, Jensen FE, Tsao B. 1992. Three-dimensional structure of dendritic spines and synapses in rat hippocampus (CA1) at postnatal day 15 and adult ages: implications for the maturation of synaptic physiology and long-term potentiation. J Neurosci. 12:2685-2705.
20. Hernandez-Flores T, Hernandez-Gonzalez O, Perez-Ramirez M B, Lara-Gonzalez E, Arias-Garcia MA, Duhne M, Perez-Burgos A, Prieto GA, et al. 2015. Modulation of direct pathway striatal projection neurons by muscarinic M(4)-type receptors. Neuropharmacol. 89:232-244.
21. Ingham CA, Hood SH, Arbuthnott GW. 1989. Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res. 503:334-338.
22. Jenner P. 2008. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 9:665-677.
23. Kawaguchi Y. 1997. Neostriatal cell subtypes and their functional roles. Neurosci Res. 27:1-8.
24. Lazcano Z, Solis O, Díaz A, Brambila E, Aguilar-Alonso P, Guevara J, Flores G. 2015. Dendritic morphology changes in neurons from the ventral hippocampus, amygdala and nucleus accumbens in rats with neonatal lesions into the prefrontal cortex. Synapse. 69(6):314-25.
25. Lujan R, Nusser Z, Roberts JD, Shigemoto R, Somogyi P. 1996. Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur J Neurosci. 8:1488-1500.
26. McNeill TH, Brown SA, Rafols JA, Shoulson I. 1988. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res. 455:148-152.
27. Murer MG, Moratalla R. 2011. Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front Neuroanat. 5:51.
28. Parker PR, Lalive AL, Kreitzer AC. 2016. Pathway-specific remodeling of thalamostriatal synapses in parkinsonian mice. Neuron. 89(4):734-740.
29. Pavon N, Martin AB, Mendialdua A, Moratalla R. 2006. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry. 59:64-74.
30. Perez-Ortega J, Duhne M, Lara-Gonzalez E, Plata V, Gasca D, Galarraga E, Hernandez-Cruz A, Bargas J. 2016. Pathophysiological signatures of functional connectomics in parkinsonian and dyskinetic striatal microcircuits. Neurobiol Dis. doi:10. 1016/j. nbd. 2016. 02. 023.
31. Plata V, Duhne M, Pérez-Ortega J, Hernández-Martinez R, Rueda-Orozco P, Galarraga E, Drucker-Colín R, Bargas J. 2013. Global actions of nicotine on the striatal microcircuit. Front Syst Neurosci. 6(7):78.
32. Porras G, Berthet A, Dehay B, Li Q, Ladepeche L, Normand E, Dovero S, Martinez A, Doudnikoff E, Martin-Negrier ML, Chuan Q, Bloch B, Choquet D, Boue-Grabot E, Groc L, Bezard E. 2012. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Neurosci. 122:3977-3989.
33. Robinson TE, Kolb B. 2004. Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology. 47(Suppl 1): 33-46.
34. Rodriguez A, Ehlenberger DB, Dickstein DL, Hof PR, Wearne SL. 2008. Automated three-dimensional detection and shape classification of dendritic spines from fluorescence microscopy images. PLoS One. 3:e1997.
35. Ruiz-DeDiego I, Mellstrom B, Vallejo M, Naranjo JR, Moratalla R. 2015. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice. Biol Psychiatry. 77: 95-105.
36. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, et al. 2007. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 27:6995-7005.
37. Solis O, Espadas I, Del-Bel EA, Moratalla R. 2015a. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice. Neurobiol Dis. 73:49-59.
38. Solís, O., Garcia-Montes, J.R., González-Granillo, A., Xu, M., Moratalla, R., Dopamine D3 receptor modulates L-DOPA-induced dyskinesia by targeting D1 receptor-mediated striatal signaling. Cereb. Cortex, 2015, 27(1): 435-446.
39. Solis O, Limón DI, Flores-Hernández J, Flores G. 2007. Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease. Synapse. 61:450-458.
40. Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW, Bell JE, Kilford L, Kingsbury AE, Daniel SE, Ingham CA. 2005. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience. 132: 741-754.
41. Stuart G, Spruston N, Sakmann B, Häusser M. 1997. Action potential initiation and backpropagation in neurons of the mammalian CNS. Trends Neurosci. 20 (3):125-131.
42. Suarez LM, Solis O, Carames JM, Taravini IR, Solis JM, Murer MG, Moratalla R. 2014. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry. 75:711-722.
43. Surmeier DJ, Bargas J, Hemmings HCJr, Nairn AC, Greengard P. 1995. Modulation of calcium currents by a D1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron. 14:385-397.
44. Toy WA, Petzinger GM, Leyshon BJ, Akopian GK, Walsh JP, Hoffman M V, Vuckovíc MG, Jakowec MW. 2014. Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Neurobiol Dis. 63:201-209.
45. Usowicz MM, Sugimori M, Cherksey B, Llinas R. 1992. P-type calcium channels in the somata and dendrites of adult cerebellar Purkinje cells. Neuron. 9:1185-99.
46. Villalba R M, Wichmann T, Smith Y. 2014. Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease. Brain Struct Funct. 219:381-394.
47. Villalba RM, Lee H, Smith Y. 2009. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp Neurol. 215:220-227.
48. Westenbroek RE, Hell JW, Warner C, Dubel SJ, Snutch TP, Catterall WA. 1992. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron. 9:1099-1115.
49. Yuste R, Bonhoeffer T. 2004. Genesis of dendritic spines: insights from ultrastructural and imaging studies. Nat Rev Neurosci. 5:24-34.
50. Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ. 2005. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology. 64:545-547.
51. Zhang Y, Meredith GE, Mendoza-Elias N, Rademacher DJ, Tseng KY, Steece-Collier K. 2013. Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses. J Neurosci. 33:11655-11667.